This site is intended for UK healthcare professionals only and contains promotional information.UK Flag Please visit the MHRA Yellowcard site to report an Adverse Event.

Positioning quinolones in the support of infection management in Scotland

Prescribing Information for QUOFENIX®(delafloxacin), VABOREM®(meropenem/vaborbactam) and TENKASI®(oritavancin) can be found below

Positioning quinolones in the support of infection management in Scotland

Presented by: Dr John Cunniffe, Consultant Microbiologist, Countess of Chester NHS Foundation Trust, Cheshire. SMC Scotland, 8th September 2022.

Professor John E Moore, CF Consultant Microbiologist Northern Ireland Regional Adult Cystic Fibrosis Centre, Belfast City Hospital.

Content Summary: 1. In July 2022 SMC published their assessment on QUOFENIX (delafloxacin) for treatment of ABSSSI (for full guidance click here delafloxacin (Quofenix) (scottishmedicines.org.uk).
2. The potential role of a quinolone in assisting early discharge with patients with complex SSTI.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to A. Menarini Farmaceutica Internazionale SRL. Phone 0800 085 8678 or email: [email protected]


These medicinal products are subject to additional monitoring.

Dr John Cunniffe

Dr John Cunniffe

John Cunniffe recently retired from Wirral University Teaching Hospital, where he was a Consultant in Medical Microbiology. At various points in post he held the positions of Head of Department, Joint Laboratory Service Lead, Director of Infection Prevention and Control (DIPC), Antimicrobial Stewardship Lead, and Clinical Lead for the Wirral Outpatient Antimicrobial Therapy (OPAT) Service. In addition, he was the Clinical Microbiology Lead and Infection Control Doctor for Clatterbridge Cancer Centre until the service relocated to Liverpool in 2020. He was a long-standing Drug and Therapeutics panel member for both Trusts.

Professor John Moore

Professor John Moore

Professor John E. Moore is Clinical Microbiologist at Belfast City Hospital, incorporating the Northern Ireland Public Health Laboratory, where he has worked since 1993. Belfast City Hospital is a university teaching hospital of Queen’s University of Belfast Medical School, as well as the Regional Centre in Northern Ireland for adults with cystic fibrosis. He is Honorary Professor in the School of Medicine, Dentistry and Biomedical Sciences, Queen’s University, Belfast, as well as Honorary Professor in the School of Biomedical Sciences, Ulster University, and past External Examiner for Clinical Microbiology at Trinity College, Dublin. His clinical and research interests include the microbiology of cystic fibrosis, on which he has published approximately 100 peer-reviewed publications, as well as antimicrobial resistance.

PP-AI-UK-0486 April 2024

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk or search for MHRA Yellow Card in Google Play or Apple App Store.

Adverse events should also be reported to A. Menarini Farmaceutica Internazionale SRL.

Phone 0800 085 8678